Media Summary: Prof. Chi on first results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in ... In this episode, we explore the groundbreaking findings from the EMBARK trial, highlighting how enzalutamide, both in ... Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses ...
Mdv 3100 - Detailed Analysis & Overview
Prof. Chi on first results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in ... In this episode, we explore the groundbreaking findings from the EMBARK trial, highlighting how enzalutamide, both in ... Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses ... Celestia Higano, MD, of the University of Washington in Seattle, speaks about the long term efficacy of Rational combination therapy for Enzalutamide ( LBA12_PR - PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate ...
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland ... Daniel P. Petrylak, MD, examines ARCHES trial data that concludes, for patients with CSPC, ENZA + ADT improves rPFS over ... Maha H. Hussain, MD, FACP, Genevieve Teuton Professor of Medicine, deputy director, Robert H. Lurie Comprehensive Cancer ... Judd W. Moul, MD, and Charles J. Ryan, MD, discuss the evolving role of enzalutamide in the context of nonmetastatic ... Judd W. Moul, MD; Julie Graff, MD; and Charles J. Ryan, MD, highlight which approaches most excite them in the future treatment ... Apalutamide, darolutamide and enzalutamide are androgen-receptor signaling inhibitors proved to be useful in patients with ...
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, ... prostatecancer -2 TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO demonstrated that using TALZENNA, ... The panelists, Raoul S. Concepcion, MD, FACS; Michael Fabrizio, MD, FACS; Jorge A. Garcia, MD, FACP; Charles J. Ryan, MD; ... Immune Therapy is an important tool for advanced prostate cancer disease, especially in older patients for whom chemotherapy is ...
